Anterior Uveitis - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Anterior Uveitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Anterior Uveitis - Pipeline Review, H2 2016', provides an overview of the Anterior Uveitis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Anterior Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anterior Uveitis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anterior Uveitis
- The report reviews pipeline therapeutics for Anterior Uveitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Anterior Uveitis therapeutics and enlists all their major and minor projects
- The report assesses Anterior Uveitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Anterior Uveitis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Anterior Uveitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anterior Uveitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Anterior Uveitis Overview 6
Therapeutics Development 7
Pipeline Products for Anterior Uveitis - Overview 7
Anterior Uveitis - Therapeutics under Development by Companies 8
Anterior Uveitis - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Anterior Uveitis - Products under Development by Companies 12
Anterior Uveitis - Companies Involved in Therapeutics Development 13
Aciont Inc. 13
Aldeyra Therapeutics, Inc. 14
EyeGate Pharmaceuticals, Inc. 15
KPI Therapeutics, Inc. 16
Neuroptis Biotech 17
Anterior Uveitis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
dalazatide - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
dexamethasone acetate - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
dexamethasone sodium phosphate - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
LME-636 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
NOP-3 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
NS-2 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Anterior Uveitis - Dormant Projects 44
Anterior Uveitis - Discontinued Products 45
Anterior Uveitis - Product Development Milestones 46
Featured News & Press Releases 46
May 09, 2016: Aldeyra Therapeutics Announces Positive Results From Phase II Clinical Trial in Subjects With Noninfectious Anterior Uveitis 46
Mar 02, 2016: EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals for EGP-437 47
Jan 19, 2016: EyeGate Pharma Enrolls First Patient in Confirmatory Phase 3 Clinical Trial EGP-437-006 for Non-Infectious Anterior Uveitis 47
May 04, 2015: EyeGate Pharma Receives Positive Guidance From FDA on NDA Filing Requirements of EGP-437 for the Treatment of Anterior Uveitis 48
Apr 16, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase II Clinical Trial 49
Mar 26, 2015: Aldeyra Therapeutics Opens Enrollment in Noninfectious Anterior Uveitis Phase II Clinical Trial 49
Mar 19, 2015: Kineta's ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases 49
Mar 02, 2015: Aldeyra Therapeutics Provides Update on NS2 Clinical Program 50
Feb 17, 2015: Kineta to Present New, Positive Data for ShK-186 in Autoimmune Eye Diseases and in ANCA Vasculitis at Upcoming Prestigious Science Conferences 50
Dec 18, 2014: Aldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis 51
Apr 09, 2013: EyeGate Pharma's EGP-437 Matches Standard-of-care's Response Rate In Phase III Study In Patients With Anterior Uveitis 51
Dec 18, 2012: EyeGate Pharma Enrolls Last Patient In Pivotal Phase III Anterior Uveitis Study Of EGP-437 52
Jan 05, 2012: EyeGate Pharma Initiates Phase III Study Of EGP-437 In Patients With Anterior Uveitis 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables

Number of Products under Development for Anterior Uveitis, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Anterior Uveitis - Pipeline by Aciont Inc., H2 2016 13
Anterior Uveitis - Pipeline by Aldeyra Therapeutics, Inc., H2 2016 14
Anterior Uveitis - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2016 15
Anterior Uveitis - Pipeline by KPI Therapeutics, Inc., H2 2016 16
Anterior Uveitis - Pipeline by Neuroptis Biotech, H2 2016 17
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Stage and Target, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Anterior Uveitis - Dormant Projects, H2 2016 44
Anterior Uveitis - Discontinued Products, H2 2016 45